{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T14:21:29Z","timestamp":1776522089144,"version":"3.51.2"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008388","name":"Radiumhospitalets Forskningsstifltelse","doi-asserted-by":"publisher","award":["TARACAN"],"award-info":[{"award-number":["TARACAN"]}],"id":[{"id":"10.13039\/501100008388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008388","name":"Radiumhospitalets Forskningsstifltelse","doi-asserted-by":"publisher","award":["TARACAN"],"award-info":[{"award-number":["TARACAN"]}],"id":[{"id":"10.13039\/501100008388","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ARTBIO AS"},{"name":"European Union\u2019s Horizon 2020 research and innovation programme","award":["No 101008571 (PRISMAP)"],"award-info":[{"award-number":["No 101008571 (PRISMAP)"]}]},{"name":"Prostate Cancer UK Career Acceleration Fellowship","award":["TLD-PF21-001"],"award-info":[{"award-number":["TLD-PF21-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-29785-7","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T19:53:02Z","timestamp":1764445982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [212Pb]Pb-AB001"],"prefix":"10.1038","volume":"16","author":[{"given":"Vilde Yuli","family":"Stenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rugile","family":"Liukaityte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra Kvarsvik","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Wangen-Riise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrius","family":"Kleinauskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asta","family":"Juzeniene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"29785_CR1","doi-asserted-by":"publisher","first-page":"877379","DOI":"10.3389\/fonc.2022.877379","volume":"12","author":"F Moreira-Silva","year":"2022","unstructured":"Moreira-Silva, F., Henrique, R. & Jer\u00f3nimo, C. From therapy resistance to targeted therapies in prostate cancer. Front. Oncol. 12, 877379. https:\/\/doi.org\/10.3389\/fonc.2022.877379 (2022).","journal-title":"Front. Oncol."},{"key":"29785_CR2","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1007\/s00259-023-06340-y","volume":"50","author":"S Ballal","year":"2023","unstructured":"Ballal, S. et al. Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study. Eur. J. Nucl. Med. Mol. Imaging. 50, 3777\u20133789. https:\/\/doi.org\/10.1007\/s00259-023-06340-y (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"29785_CR3","doi-asserted-by":"publisher","unstructured":"Juzeniene, A., Stenberg, V. Y., Bruland, \u00d8., Larsen, R. H. & S. & Preclinical and clinical status of PSMA-Targeted alpha therapy for metastatic Castration-Resistant prostate cancer. Cancers (Basel). 13. https:\/\/doi.org\/10.3390\/cancers13040779 (2021).","DOI":"10.3390\/cancers13040779"},{"key":"29785_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/pros.24857","volume":"85","author":"H Besiroglu","year":"2025","unstructured":"Besiroglu, H. & Kadihasanoglu, M. The safety and efficacy of targeted alpha Therapy, Ac-225 prostate-Specific membrane Antigen, in patients with metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis. Prostate 85, 541\u2013557. https:\/\/doi.org\/10.1002\/pros.24857 (2025).","journal-title":"Prostate"},{"key":"29785_CR5","doi-asserted-by":"publisher","first-page":"e14358","DOI":"10.1111\/eci.14358","volume":"55","author":"ML Garo","year":"2025","unstructured":"Garo, M. L., Ov\u010dari\u010dek, P. P., Fanti, S. & Giovanella, L. [225Ac]Ac-PSMA for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. Eur. J. Clin. Invest. 55, e14358. https:\/\/doi.org\/10.1111\/eci.14358 (2025).","journal-title":"Eur. J. Clin. Invest."},{"key":"29785_CR6","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.7150\/thno.106574","volume":"15","author":"G Ninatti","year":"2025","unstructured":"Ninatti, G. et al. Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis. Theranostics 15, 3386\u20133399. https:\/\/doi.org\/10.7150\/thno.106574 (2025).","journal-title":"Theranostics"},{"key":"29785_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis, A. et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur. Urol. 76, 469\u2013478. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.030 (2019).","journal-title":"Eur. Urol."},{"key":"29785_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1358\/dot.2023.59.1.3476574","volume":"59","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Lutetium Lu 177 Vipivotide tetraxetan for prostate cancer. Drugs Today (Barc). 59, 37\u201349. https:\/\/doi.org\/10.1358\/dot.2023.59.1.3476574 (2023).","journal-title":"Drugs Today (Barc)"},{"key":"29785_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic Castration-Resistant prostate cancer. N Engl. J. Med. 385, 1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322 (2021).","journal-title":"N Engl. J. Med."},{"key":"29785_CR10","doi-asserted-by":"publisher","unstructured":"Mattana, F. et al. Prostate-Specific membrane Antigen-Targeted therapy in prostate cancer: History, combination Therapies, Trials, and future perspective. Cancers (Basel). 16. https:\/\/doi.org\/10.3390\/cancers16091643 (2024).","DOI":"10.3390\/cancers16091643"},{"key":"29785_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07390-0","author":"Z Song","year":"2025","unstructured":"Song, Z. et al. Targeted alpha therapy: a comprehensive analysis of the biological effects from local-regional-systemic dimensions. Eur. J. Nucl. Med. Mol. Imaging. https:\/\/doi.org\/10.1007\/s00259-025-07390-0 (2025).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"29785_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s002590100484","volume":"28","author":"JP Pouget","year":"2001","unstructured":"Pouget, J. P. & Mather, S. J. General aspects of the cellular response to low- and high-LET radiation. Eur. J. Nucl. Med. 28, 541\u2013561. https:\/\/doi.org\/10.1007\/s002590100484 (2001).","journal-title":"Eur. J. Nucl. Med."},{"key":"29785_CR13","doi-asserted-by":"publisher","first-page":"692436","DOI":"10.3389\/fmed.2021.692436","volume":"8","author":"JP Pouget","year":"2021","unstructured":"Pouget, J. P. & Constanzo, J. Revisiting the radiobiology of targeted alpha therapy. Front. Med. (Lausanne). 8, 692436. https:\/\/doi.org\/10.3389\/fmed.2021.692436 (2021).","journal-title":"Front. Med. (Lausanne)"},{"key":"29785_CR14","doi-asserted-by":"publisher","first-page":"1020188","DOI":"10.3389\/fmed.2022.1020188","volume":"9","author":"RM Pallares","year":"2022","unstructured":"Pallares, R. M. & Abergel, R. J. Development of radiopharmaceuticals for targeted alpha therapy: where do we stand? Front. Med. (Lausanne). 9, 1020188. https:\/\/doi.org\/10.3389\/fmed.2022.1020188 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"29785_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2967\/jnumed.123.266774","volume":"65","author":"R Zimmermann","year":"2024","unstructured":"Zimmermann, R. Is 212Pb really happening? The Post-177Lu\/225Ac blockbuster? J. Nucl. Med. 65, 176\u2013177. https:\/\/doi.org\/10.2967\/jnumed.123.266774 (2024).","journal-title":"J. Nucl. Med."},{"key":"29785_CR16","doi-asserted-by":"publisher","unstructured":"Khazaei Monfared, Y. et al. DNA damage by radiopharmaceuticals and mechanisms of cellular repair. Pharmaceutics 15 https:\/\/doi.org\/10.3390\/pharmaceutics15122761 (2023).","DOI":"10.3390\/pharmaceutics15122761"},{"key":"29785_CR17","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/s12276-022-00863-4","volume":"54","author":"Y Abuetabh","year":"2022","unstructured":"Abuetabh, Y. et al. DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities. Exp. Mol. Med. 54, 1658\u20131669. https:\/\/doi.org\/10.1038\/s12276-022-00863-4 (2022).","journal-title":"Exp. Mol. Med."},{"key":"29785_CR18","doi-asserted-by":"publisher","unstructured":"Williams, A. B. (ed, B.) p53 in the DNA-Damage-Repair process. Cold Spring Harb Perspect. Med. 6 https:\/\/doi.org\/10.1101\/cshperspect.a026070 (2016).","DOI":"10.1101\/cshperspect.a026070"},{"key":"29785_CR19","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2967\/jnumed.120.256263","volume":"62","author":"AD Stuparu","year":"2021","unstructured":"Stuparu, A. D. et al. Mechanisms of resistance to prostate-Specific membrane Antigen-Targeted radioligand therapy in a mouse model of prostate cancer. J. Nucl. Med. 62, 989\u2013995. https:\/\/doi.org\/10.2967\/jnumed.120.256263 (2021).","journal-title":"J. Nucl. Med."},{"key":"29785_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03704-9","author":"EM Kwan","year":"2025","unstructured":"Kwan, E. M. et al. Lutetium-177-PSMA-617 or Cabazitaxel in metastatic prostate cancer: Circulating tumor DNA analysis of the randomized phase 2 therap trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-03704-9 (2025).","journal-title":"Nat. Med."},{"key":"29785_CR21","doi-asserted-by":"publisher","first-page":"e2300634","DOI":"10.1200\/po.23.00634","volume":"8","author":"R Raychaudhuri","year":"2024","unstructured":"Raychaudhuri, R. et al. Genomic correlates of Prostate-Specific membrane antigen expression and response to 177Lu-PSMA-617: A retrospective multicenter cohort study. JCO Precis Oncol. 8, e2300634. https:\/\/doi.org\/10.1200\/po.23.00634 (2024).","journal-title":"JCO Precis Oncol."},{"key":"29785_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.119.234559","volume":"61","author":"C Kratochwil","year":"2020","unstructured":"Kratochwil, C. et al. Patients resistant against PSMA-Targeting \u03b1-Radiation therapy often harbor mutations in DNA Damage-Repair-Associated genes. J. Nucl. Med. 61, 683\u2013688. https:\/\/doi.org\/10.2967\/jnumed.119.234559 (2020).","journal-title":"J. Nucl. Med."},{"key":"29785_CR23","doi-asserted-by":"publisher","first-page":"6248","DOI":"10.1038\/s41467-021-26489-0","volume":"12","author":"M Fraser","year":"2021","unstructured":"Fraser, M. et al. Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. Nat. Commun. 12, 6248. https:\/\/doi.org\/10.1038\/s41467-021-26489-0 (2021).","journal-title":"Nat. Commun."},{"key":"29785_CR24","doi-asserted-by":"publisher","unstructured":"Ofner, H., Kramer, G., Shariat, S. F. & Hassler, M. R. TP53 deficiency in the natural history of prostate cancer. Cancers (Basel). 17. https:\/\/doi.org\/10.3390\/cancers17040645 (2025).","DOI":"10.3390\/cancers17040645"},{"key":"29785_CR25","doi-asserted-by":"publisher","unstructured":"Zhang, H. et al. Unraveling the Guardian: p53\u2019s Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies. Int. J. Mol. Sci. 25 https:\/\/doi.org\/10.3390\/ijms252312928 (2024).","DOI":"10.3390\/ijms252312928"},{"key":"29785_CR26","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/sj.onc.1204252","volume":"20","author":"WR Taylor","year":"2001","unstructured":"Taylor, W. R. & Stark, G. R. Regulation of the G2\/M transition by p53. Oncogene 20, 1803\u20131815. https:\/\/doi.org\/10.1038\/sj.onc.1204252 (2001).","journal-title":"Oncogene"},{"key":"29785_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jlcr.3825","volume":"63","author":"VY Stenberg","year":"2020","unstructured":"Stenberg, V. Y. et al. Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212Pb]Pb-NG001 for prostate cancer. J. Label. Comp. Radiopharm. 63, 129\u2013143. https:\/\/doi.org\/10.1002\/jlcr.3825 (2020).","journal-title":"J. Label. Comp. Radiopharm"},{"key":"29785_CR28","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.3390\/ijms22094815","volume":"22","author":"VY Stenberg","year":"2021","unstructured":"Stenberg, V. Y. et al. Evaluation of the PSMA-Binding ligand 212Pb-NG001 in multicellular tumour spheroid and mouse models of prostate cancer. Int. J. Mol. Sci. 22, 4815 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"29785_CR29","doi-asserted-by":"publisher","unstructured":"Stenberg, V. Y. et al. Factors influencing the therapeutic efficacy of the PSMA targeting radioligand 212Pb-NG001. Cancers (Basel). 14. https:\/\/doi.org\/10.3390\/cancers14112784 (2022).","DOI":"10.3390\/cancers14112784"},{"key":"29785_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/aja.2009.91","volume":"12","author":"BX Xie","year":"2010","unstructured":"Xie, B. X. et al. The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP. Asian J. Androl. 12, 405\u2013414. https:\/\/doi.org\/10.1038\/aja.2009.91 (2010).","journal-title":"Asian J. Androl."},{"key":"29785_CR31","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.7150\/ijbs.111732","volume":"21","author":"Z Bian","year":"2025","unstructured":"Bian, Z. et al. Modulating the immunosuppressive tumor microenvironment and inhibiting growth in Mutp53-Driven CRPC via STAT3 pathway Blockade. Int. J. Biol. Sci. 21, 3081\u20133098. https:\/\/doi.org\/10.7150\/ijbs.111732 (2025).","journal-title":"Int. J. Biol. Sci."},{"key":"29785_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s1078-1439(01)00175-2","volume":"7","author":"P Jackson","year":"2002","unstructured":"Jackson, P. et al. Relationship between expression of KAI1 metastasis suppressor gene, mRNA levels and p53 in human bladder and prostate cancer cell lines. Urol. Oncol. 7, 99\u2013104. https:\/\/doi.org\/10.1016\/s1078-1439(01)00175-2 (2002).","journal-title":"Urol. Oncol."},{"key":"29785_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/pros.22583","volume":"73","author":"C Liu","year":"2013","unstructured":"Liu, C. et al. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 73, 418\u2013427. https:\/\/doi.org\/10.1002\/pros.22583 (2013).","journal-title":"Prostate"},{"key":"29785_CR34","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.117.193359","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler, W. P. et al. Establishing 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. J. Nucl. Med. 58, 1786\u20131792. https:\/\/doi.org\/10.2967\/jnumed.117.193359 (2017).","journal-title":"J. Nucl. Med."},{"key":"29785_CR35","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3892\/ijmm.2013.1333","volume":"31","author":"JY Kim","year":"2013","unstructured":"Kim, J. Y. et al. p53 interferes with microtubule-stabilizing agent-induced apoptosis in prostate and colorectal cancer cells. Int. J. Mol. Med. 31, 1388\u20131394. https:\/\/doi.org\/10.3892\/ijmm.2013.1333 (2013).","journal-title":"Int. J. Mol. Med."},{"key":"29785_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2967\/jnumed.122.264009","volume":"64","author":"RG Li","year":"2023","unstructured":"Li, R. G., Stenberg, V. Y. & Larsen, R. H. An experimental generator for production of High-Purity 212Pb for use in radiopharmaceuticals. J. Nucl. Med. 64, 173\u2013176. https:\/\/doi.org\/10.2967\/jnumed.122.264009 (2023).","journal-title":"J. Nucl. Med."},{"key":"29785_CR37","doi-asserted-by":"publisher","first-page":"109362","DOI":"10.1016\/j.apradiso.2020.109362","volume":"166","author":"E Napoli","year":"2020","unstructured":"Napoli, E. et al. Calibration of sodium iodide detectors and reentrant ionization chambers for 212Pb activity in different geometries by HPGe activity determined samples. Appl. Radiat. Isot. 166, 109362. https:\/\/doi.org\/10.1016\/j.apradiso.2020.109362 (2020).","journal-title":"Appl. Radiat. Isot."},{"key":"29785_CR38","doi-asserted-by":"publisher","first-page":"110473","DOI":"10.1016\/j.apradiso.2022.110473","volume":"190","author":"DE Bergeron","year":"2022","unstructured":"Bergeron, D. E. et al. Primary standardization of 212Pb activity by liquid scintillation counting. Appl. Radiat. Isot. 190, 110473. https:\/\/doi.org\/10.1016\/j.apradiso.2022.110473 (2022).","journal-title":"Appl. Radiat. Isot."},{"key":"29785_CR39","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.3892\/or.2013.2364","volume":"29","author":"B van Oorschot","year":"2013","unstructured":"van Oorschot, B. et al. Decay of \u03b3-H2AX foci correlates with potentially lethal damage repair in prostate cancer cells. Oncol. Rep. 29, 2175\u20132180. https:\/\/doi.org\/10.3892\/or.2013.2364 (2013).","journal-title":"Oncol. Rep."},{"key":"29785_CR40","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1158\/1535-7163.Mct-11-0191","volume":"10","author":"X Wang","year":"2011","unstructured":"Wang, X., Ma, D., Olson, W. C. & Heston, W. D. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol. Cancer Ther. 10, 1728\u20131739. https:\/\/doi.org\/10.1158\/1535-7163.Mct-11-0191 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"29785_CR41","doi-asserted-by":"publisher","first-page":"100583","DOI":"10.1016\/j.ctro.2023.100583","volume":"39","author":"A Mesci","year":"2023","unstructured":"Mesci, A. et al. 18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer. Clin. Transl Radiat. Oncol. 39, 100583. https:\/\/doi.org\/10.1016\/j.ctro.2023.100583 (2023).","journal-title":"Clin. Transl Radiat. Oncol."},{"key":"29785_CR42","doi-asserted-by":"publisher","unstructured":"Sommer, U. et al. Impact of androgen receptor activity on prostate-Specific membrane antigen expression in prostate cancer cells. Int. J. Mol. Sci. 23 https:\/\/doi.org\/10.3390\/ijms23031046 (2022).","DOI":"10.3390\/ijms23031046"},{"key":"29785_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13550-017-0257-4","volume":"7","author":"CA Umbricht","year":"2017","unstructured":"Umbricht, C. A. et al. 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. EJNMMI Res. 7, 9. https:\/\/doi.org\/10.1186\/s13550-017-0257-4 (2017).","journal-title":"EJNMMI Res."},{"key":"29785_CR44","doi-asserted-by":"publisher","unstructured":"Raitanen, J. et al. Radiobiological Assessment of Targeted Radionuclide Therapy with [177Lu]Lu-PSMA-I&T in 2D vs. 3D Cell Culture Models. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms242317015 (2023).","DOI":"10.3390\/ijms242317015"},{"key":"29785_CR45","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1007\/s00259-019-04434-0","volume":"46","author":"SR Banerjee","year":"2019","unstructured":"Banerjee, S. R. et al. 177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. Eur. J. Nucl. Med. Mol. Imaging. 46, 2545\u20132557. https:\/\/doi.org\/10.1007\/s00259-019-04434-0 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"29785_CR46","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1007\/s00259-023-06229-w","volume":"50","author":"X Wen","year":"2023","unstructured":"Wen, X. et al. Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur. J. Nucl. Med. Mol. Imaging. 50, 2846\u20132860. https:\/\/doi.org\/10.1007\/s00259-023-06229-w (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"29785_CR47","doi-asserted-by":"publisher","unstructured":"Maes, J. et al. Prostate-Specific membrane antigen biology and pathophysiology in prostate Carcinoma, an update: potential implications for targeted imaging and therapy. Int. J. Mol. Sci. 25 https:\/\/doi.org\/10.3390\/ijms25179755 (2024).","DOI":"10.3390\/ijms25179755"},{"key":"29785_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/antib1020124","volume":"1","author":"H Song","year":"2012","unstructured":"Song, H., Senthamizhchelvan, S., F Hobbs, R. & Sgouros, G. Alpha particle emitter radiolabeled antibody for metastatic cancer: what can we learn from heavy ion beam radiobiology? Antibodies 1, 124\u2013148 (2012).","journal-title":"Antibodies"},{"key":"29785_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/mirt.galenos.2021.63308","volume":"31","author":"H Lee","year":"2022","unstructured":"Lee, H. Relative efficacy of 225Ac-PSMA-617 and 177Lu-PSMA-617 in prostate cancer based on subcellular dosimetry. Mol. Imaging Radionucl. Ther. 31, 1\u20136. https:\/\/doi.org\/10.4274\/mirt.galenos.2021.63308 (2022).","journal-title":"Mol. Imaging Radionucl. Ther."},{"key":"29785_CR50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s41181-025-00382-3","volume":"10","author":"K Lindland","year":"2025","unstructured":"Lindland, K. & Juzeniene, A. Cytotoxicity of 212Pb-labeled anti-PTK7 antibody in 2D adherent and 3D multicellular bladder cancer models. EJNMMI Radiopharm Chem. 10, 58. https:\/\/doi.org\/10.1186\/s41181-025-00382-3 (2025).","journal-title":"EJNMMI Radiopharm Chem."},{"key":"29785_CR51","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1158\/1535-7163.Mct-11-0671","volume":"11","author":"KJ Yong","year":"2012","unstructured":"Yong, K. J., Milenic, D. E., Baidoo, K. E. & Brechbiel, M. W. 212Pb-radioimmunotherapy induces G2 cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol. Cancer Ther. 11, 639\u2013648. https:\/\/doi.org\/10.1158\/1535-7163.Mct-11-0671 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"29785_CR52","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1038\/bjc.2013.189","volume":"108","author":"KJ Yong","year":"2013","unstructured":"Yong, K. J., Milenic, D. E., Baidoo, K. E. & Brechbiel, M. W. 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint. Br. J. Cancer. 108, 2013\u20132020. https:\/\/doi.org\/10.1038\/bjc.2013.189 (2013).","journal-title":"Br. J. Cancer"},{"key":"29785_CR53","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1385\/mb:32:3","volume":"32","author":"GR Stark","year":"2006","unstructured":"Stark, G. R. & Taylor, W. R. Control of the G2\/M transition. Mol. Biotechnol. 32, 227\u2013248. https:\/\/doi.org\/10.1385\/mb:32:3 (2006).","journal-title":"Mol. Biotechnol."},{"key":"29785_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41420-021-00570-5","volume":"7","author":"P Li","year":"2021","unstructured":"Li, P. et al. Comparable radiation sensitivity in p53 wild-type and p53 deficient tumor cells associated with different cell death modalities. Cell. Death Discov. 7, 184. https:\/\/doi.org\/10.1038\/s41420-021-00570-5 (2021).","journal-title":"Cell. Death Discov"},{"key":"29785_CR55","doi-asserted-by":"publisher","unstructured":"Dunne, V. L. et al. Synergistic activity of DNA damage response inhibitors in combination with Radium-223 in prostate cancer. Cancers (Basel). 16. https:\/\/doi.org\/10.3390\/cancers16081510 (2024).","DOI":"10.3390\/cancers16081510"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29785-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29785-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29785-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:36:56Z","timestamp":1767706616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29785-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["29785"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29785-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Two authors (V.Y.S.\u00a0and R.L.) were employees of ARTBIO AS at the time the work was conducted,. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}